Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Prosman™ for Benign Prostatic Hyperplasia
NCT07145034Not yet recruiting
- Sponsor
- AIIMS New Delhi
- Start
- Sep 2025
- Primary completion
- May 2026
01
Overview
Randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Prosman with Placebo (2 arms). Primary endpoint: International Prostate Symptom Score at 8 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Prunus domestica extract
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07145034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145034.